Aeterna Zentaris (NASDAQ:AEZS) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Price Performance

NASDAQ AEZS opened at $5.72 on Friday. The company has a market cap of $10.26 million, a P/E ratio of -0.28 and a beta of 1.55. The stock has a 50-day moving average of $5.14 and a two-hundred day moving average of $6.66. Aeterna Zentaris has a 1-year low of $3.96 and a 1-year high of $12.00.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.